The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.
在说明书中披露的公式(1)化合物的使用,其中R1、R2、R3、R4、R5和R6可独立选择为
氢、烷基和芳基,或其药用盐,但其中R1至R4和R6为
氢时,R5不可选择自CH2CH2NHSO2CH3、CH2CH2NHSO2CF3和
甲基被SO2NH2、SO3H、PO3H2、CONHOH或从公式(a)、(b)、(c)、(d)和(e)中选择的杂环基团,用于制造用于治疗通常与谷
氨酸能传递异常相关的病况的药物。